Form 4: BioLife Solutions Executive's Stock Vesting & Tax Withholding

BioLife Solutions' Chief Quality and Operations, Karen A. Foster, reported the vesting of restricted stock and subsequent tax-related share withholding.

Summary

• Karen A. Foster, Chief Quality and Operations of BioLife Solutions Inc. (BLFS), reported transactions involving common stock.
• On February 24, 2026, 32,112 shares of common stock were acquired due to the vesting of restricted stock.
• The restricted stock vested at approximately 156% of the original grant, based on the company's total shareholder return compared to a pre-determined peer group from January 1, 2024, to December 31, 2025.
• Concurrently, 13,013 shares were disposed of at $22.65 per share to cover tax withholding obligations associated with the vesting.
• Following these transactions, Karen A. Foster beneficially owns 211,083 shares of BioLife Solutions common stock.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive indicator of company performance relative to its peers, as evidenced by the high vesting percentage of executive restricted stock, reflecting strong shareholder returns during the performance period.

Positives

• The restricted stock vested at approximately 156% of the granted shares, indicating strong performance relative to the company's peer group during the performance period.

Negatives

• 13,013 shares were disposed of to cover tax withholding obligations, which is a routine event but represents a reduction in direct ownership.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future outlook.

Industry Context

StockSavvy.ai notes that performance-based restricted stock awards are a common executive compensation tool, designed to align management incentives with shareholder returns. The 156% vesting suggests strong relative performance within the biotech/life sciences sector for BioLife Solutions during the specified period, indicating effective execution against strategic goals compared to its competitors.

Comparison to Industry Standards

• Performance-based vesting at 156% is a strong outcome, indicating BioLife Solutions' total shareholder return outperformed its peer group during the performance period.
• The use of restricted stock awards tied to total shareholder return relative to peers is a standard and widely accepted practice in executive compensation across various industries, including biotechnology and life sciences.

Corporate Governance

Stakeholder Impact

• Shareholders: The high vesting percentage suggests strong past performance relative to peers, which could be viewed positively as an indicator of management effectiveness.
• Management: Karen A. Foster's compensation is directly tied to company performance, aligning her interests with those of shareholders.

Key Dates

Recommendation

This Form 4 reports a routine vesting of performance-based restricted stock and subsequent tax withholding by a key executive. While the 156% vesting indicates strong past performance relative to peers, it does not provide new fundamental information to warrant a change in investment thesis. It primarily confirms the effectiveness of the company's executive compensation structure in aligning incentives with shareholder returns, suggesting a 'hold' recommendation as it's a positive but expected operational event.

Keywords

BioLife Solutions, BLFS, Form 4, insider transaction, stock vesting, restricted stock, executive compensation, Karen A. Foster